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Abstract  2 
Word count = 255 (/300) 3 
Objectives: Healthcare systems increasingly recognise the importance of service users’ 4 
perspectives for improving care organisation and delivery. The English Cancer Patient 5 
Experience Survey (CPES) is carried out annually, however, its representativeness within 6 
cancer types is unknown. We have explored if the CPES results are representative of people 7 
with lung cancer. 8 
Materials and methods: We linked cancer registry data across multiple sources to assess 9 
how CPES represents sociodemographic and clinical characteristics of the National Lung 10 
Cancer Audit population, accounting for post-sampling mortality bias. Multivariable logistic 11 
regression was used to compare people included and not included in CPES. 12 
Results: Of 240,375 people diagnosed (2009-2015), 15,967 (7%) were included in CPES. 13 
Gender and ethnicity were reasonably represented, as were sociodemographic and clinical 14 
groupings, although more received anti-cancer treatment (96% of CPES respondents vs. 56% 15 
of patients nationally; adjusted odds ratio=10.3, 95% confidence interval 9.4-11.2 for any 16 
anti-cancer treatment) with chemotherapy most over-represented, followed by surgery and 17 
then radiotherapy. CPES under-represented older, more socioeconomically deprived, and 18 
certain clinical groups, including those with worse performance status, multiple 19 
comorbidities, and diagnosis via emergency presentation. 20 
Conclusion: CPES includes patients across the sociodemographic and clinical spectrum 21 
indicating its value for research and service planning. Unbalanced representation of incident 22 
lung cancer cases is a limitation that must be considered in context of using CPES findings to 23 
implement service changes. Although half the national lung cancer population who received 24 
no anti-cancer treatment do not have their experiences represented, the strength of this dataset 25 
is in providing detailed comparisons of patient experiences across different treatment groups.  26 
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1. Introduction 1 
Survival after diagnosis of lung cancer appears to be lower in the UK compared with other 2 
western and European countries, despite recent improvements [1, 2]. Inequalities in the 3 
receipt of anti-cancer treatment have been reported with effective treatment under-utilised 4 
and uptake of active treatment lower in the UK compared with Scandinavian and North 5 
American countries who have better survival [3-6].  6 
Recommendations have been made by the National Institute of Health and Care Excellence to 7 
improve the quality of cancer care in England including the training of specialist cancer 8 
nurses to help identify the needs of people diagnosed with cancer and provide support 9 
throughout the cancer pathway, and involving people in decisions that shape or reshape their 10 
own cancer care including anti-cancer treatment options [7]. There has been significant 11 
investment of resource in surveys measuring patient experience to provide information on the 12 
quality of healthcare directly from the service users’ point of view [8]. The National Lung 13 
Cancer Audit (NLCA) is now a leading national audit and one of the largest and most 14 
detailed on lung cancer internationally, however it lacks a programme for patient reported 15 
outcome or experience measures. 16 
For healthcare service providers, feedback from patient experience surveys helps to identify 17 
where cancer services can focus efforts to improve care [9, 10]. For service users, this helps 18 
in making choices about their care and for quality assurance. The English National Cancer 19 
Patient Experience Survey (CPES) was commissioned by the Department of Health for this 20 
purpose and is carried out annually by Quality Health. Feedback from similar patient 21 
experience surveys has been successful in informing healthcare service quality in outpatient 22 
departments and patient-doctor interaction in countries such as Australia, Finland and the 23 
USA [11-13]. For CPES to achieve its purpose, it is important to understand how patients 24 
responding to the survey represent people diagnosed with lung cancer in England.  It 25 
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currently obtains responses from over 65,000 people with cancer each year, approximately 1 
6% of whom have lung cancer; this representation relative to the incidence of lung cancer is 2 
lower than for many other tumour sites, particularly breast cancer [14, 15], which may 3 
partially reflect CPES’s sampling frame of selecting people recently discharged from hospital 4 
treatment episodes.  Post-sampling mortality and sociodemographic variation in survey 5 
response patterns in CPES has been assessed across all cancer types [16]. Assessment of how 6 
CPES respondents are representative of the whole incident cancer population, however, has 7 
not been conducted, which is arguably important for the application of CPES in changing 8 
cancer services that serve all people with cancer. To do this, a comprehensive assessment for 9 
each cancer type is required, that includes detailed comparisons between individuals’ clinical 10 
and treatment pathways as well as their sociodemographic characteristics. This opportunity 11 
has only recently arisen through the individual patient linkage of CPES to national cancer 12 
registry data. 13 
We used national cancer registry data (from the NLCA) linked across multiple sources 14 
including route to diagnosis, anti-cancer treatments and long-term follow up, to assess how 15 
people with incident diagnoses of lung cancer included in CPES represent the 16 
sociodemographic, clinical, treatment characteristics and survival of the whole incident lung 17 
cancer population in England. 18 
  19 
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2. Materials and methods 1 
2.1 Study population and data sources  2 
Information on all people in England with a new primary diagnosis of lung cancer 3 
(International Classification of Diseases (ICD-10) codes C34*) between 2009 and 2015 was 4 
obtained from the National Cancer Registration and Analysis Service (NCRAS) run by Public 5 
Health England (PHE). NCRAS forms the most complete source of information on all people 6 
diagnosed with incident cancer by obtaining information from across the National Health 7 
Service (NHS), which covers 98-99% of all hospital activity in England. The NLCA 8 
comprises those individuals in NCRAS with a lung cancer diagnosis. We also accessed linked 9 
survey results of those included in at least one wave of the national CPES between 2010 and 10 
2015 (waves 1:2010, 2:2011, 3:2012, 4:2013, 5:2015). 11 
2.1.1 The National Cancer Patient Experience Survey (CPES) 12 
CPES collects self-reported information from people diagnosed with cancer about their 13 
experience of primary care pre-diagnosis, ongoing clinical management and longer-term 14 
support. It includes over 70 questions across 12 different domains. The survey is sent to all 15 
people in England aged 16 years and older with a primary diagnosis of cancer (identified 16 
using ICD-10 codes, excluding C44-other malignant neoplasms of the skin and C84-17 
peripheral and cutaneous T-cell lymphomas) who have been admitted as an inpatient or day-18 
case to hospital in relation to their cancer and discharged within the specified survey period 19 
each year (usually a three-month window, with some variation across waves). People are sent 20 
the survey by post, with two reminders for non-respondents; there are also options to 21 
complete wave 5 online or via telephone. All survey questions have undergone cognitive 22 
interview testing on samples of people with different types of cancer in different English 23 
regions [17].  24 
2.1.2 NCRAS data linkages 25 
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For all lung cancer patients we used information on age, gender, ethnicity, lung cancer type, 1 
stage at diagnosis, and route to diagnosis from their NCRAS record. Lung cancer 2 
morphology was defined using recorded Systematised Nomenclature of Medicine 3 
(SNOMED) codes. People whose SNOMED codes were missing or coded as unknown were 4 
classified as non-small-cell lung cancer (NSCLC) based on the method used by the NLCA to 5 
define lung cancer [3]. 6 
NCRAS records for NLCA patients were also linked at individual-level to Hospital Episode 7 
Statistics (HES) data which included all hospital inpatient, outpatient and emergency 8 
admissions. We used all relevant ICD-coded conditions in these admissions up to the lung 9 
cancer diagnosis to calculate a comorbidity score for each patient (Charlson Index) [18]. To 10 
build patient profiles of surgical, radiotherapy and chemotherapy treatments, we used 11 
admissions for surgery, radiotherapy or chemotherapy related to their lung cancer in 12 
conjunction with individual linked treatment databases, the National Radiotherapy Dataset 13 
and Systemic Anti-cancer Therapy dataset, and treatments recorded in the core cancer 14 
registry data [19, 20]. In HES data, we identified Office of Population Census and Survey 15 
Classification of Intervention version 4 codes corresponding to surgical, chemotherapy and 16 
radiotherapy treatment. In line with methods used by the NLCA to define anti-cancer 17 
treatment related to lung cancer, we define surgical resection of lung cancer within a 18 
timeframe of 1 month before to 6 months after diagnosis of lung cancer, and relevant 19 
chemotherapy or radiotherapy rounds as 1 month before to 9 months after diagnosis [3]. 20 
Survival time was calculated from their diagnosis date to their date of death obtained from 21 
the Office of National Statistics (ONS) or follow-up was truncated at the date of ONS cross-22 
check for death (28/01/2018). Household socioeconomic deprivation was measured as 23 
quintiles of the Index of Multiple Deprivation based on national census data and was linked 24 
to individuals’ records based on their home postcode. 25 
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Although we had the NCRAS record across our whole study period, we also used pre-2015 1 
NLCA data that was provided through a bespoke data collection system, called Lung Cancer 2 
Audit Data (LUCADA). Data entry in LUCADA was non-mandatory and showed some 3 
selection bias [21], however, they were entered by the multidisciplinary team (MDT) in NHS 4 
hospitals and included more detailed information on patient pathway including hospital-trust 5 
first seen, timing and method of Lung Cancer Nurse Specialist (LCNS) assessments and 6 
performance status (PS). This is the first time all of these linkages had been done collectively. 7 
PHE’s Office for Data Release (PHE ODR) conducted all individual matching procedures for 8 
people diagnosed with lung cancer from the core cancer registry to CPES and other data 9 
sources using bespoke algorithms that included NHS number and tumour type, as described 10 
on their website (www.ncin.org.uk). 11 
2.2 Statistical analysis 12 
Data management and analyses were carried out using Stata 15 (StataCorp, College Station, 13 
TX, USA). We compared proportions of key variables, including age, gender, PS, lung 14 
cancer stage, anti-cancer treatment and clinical service factors between people in CPES and 15 
the whole NLCA population from NCRAS. We used multivariate logistic regression to 16 
calculate odds ratios (OR) to quantify the extent to which being in CPES varied by these key 17 
variables. For the subset of patients with a LUCADA record we repeated the main analyses 18 
using a multilevel logistic regression model fitting patient and hospital level factors, enabling 19 
us to assess whether trust size (number of new lung cancer patients seen annually) or trust 20 
treatment specialty were associated with inclusion in CPES. 21 
We compared survival of those included and not included in CPES using the Kaplan–Meier 22 
method. To assess the potential effects of survival bias on our overall analyses, we conducted 23 
a subgroup analysis restricting the NCRAS study population to people who survived more 24 
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than 426 days after diagnosis, which was the 75th quartile of survival for people surveyed in 1 
CPES.  2 
10 
 
3. Results 1 
3.1 Study population 2 
The flow diagram (Figure 1) demonstrates how the study population was derived. From the 3 
whole NLCA population, we included only those with one primary lung cancer diagnosis (not 4 
multiple tumours) (N=244,957). We excluded individuals diagnosed before age 18 years or 5 
diagnosed upon or after their death (death certificate cases). From an initial 18,023 6 
individuals with linked CPES questionnaires, we excluded 698 individuals whose CPES 7 
records were likely to be unrelated to their lung cancer diagnosis. The final study population 8 
was 240,375 people with primary lung cancer diagnosed between 2009 and 2015, 15,967 9 
(6.6%) of whom had a linked CPES questionnaire. Of those in CPES; 2,761(17.9%), 3,327 10 
(20.8%), 3,353 (21.0%), 3,185(20.0%) and 3,341 (20.9%) were from waves 1 to 5, 11 
respectively. Seventy percent (167,210) of the 240,375 people had linked LUCADA 12 
information. 13 
3.2 Sociodemographic and clinical features 14 
Table 1 shows a multivariate logistic regression model assessing the odds of being included 15 
in CPES according to various characteristics. Inclusion increased over time, apart from a dip 16 
for people diagnosed in 2014 because CPES was not conducted that year. Overall, patients 17 
included in CPES had representation across every sociodemographic and clinical grouping, 18 
however, representativeness varied by feature and those in CPES were less likely to have 19 
missing information for stage, performance status, ethnicity and route to diagnosis. Women 20 
had a small increase in adjusted odds of being included in CPES compared with men. 21 
Adjusted odds of inclusion in CPES generally decreased with increasing age, PS, 22 
comorbidities and socioeconomic deprivation. Patients with a PS of 1-4, clinically recorded 23 
in their LUCADA record close to the time they were initially diagnosed, were less likely to 24 
be included in CPES compared with those recorded as PS0, clinically considered as fully 25 
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functional and asymptomatic (OR=0.79; 95% CI=0.39-0.16 for PS1-4 collectively compared 1 
with PS0). Compared with stage Sg1A, stages SgIB-IIIA were considerably more likely to be 2 
represented in CPES, whereas SgIV and missing stage were less likely to be represented. 3 
Ethnicity was not associated with the likelihood of inclusion in CPES, however, people in 4 
CPES were more likely to have complete information on ethnicity. All lung cancer types 5 
were included, with a small increase in representativeness of SCLC compared with NSCLC. 6 
Being diagnosed with lung cancer through the Two Week Wait NHS standard (an urgent 7 
referral requiring the person to be seen by a specialist within 14 days) was associated with a 8 
greater adjusted odds of inclusion in CPES, (OR=1.26; 95% CI=1.21-1.32), whilst 9 
emergency presentation was associated with a lower odds of inclusion (OR=0.52; 95% 10 
CI=0.49-0.55) compared with primary care referral. 11 
People included in CPES had considerably longer survival from diagnosis; (median survival 12 
was 158 days for those not in CPES and 774 days for those included in CPES (Figure 2a). 13 
When the analysis was restricted to all NLCA patients who survived more than 426 days, the 14 
75
th
 quartile of survival for those in CPES, this did not result in the CPES population being 15 
more evenly representative despite similar survival (Figure 2b). Results across 16 
sociodemographic and clinical features were very similar to the original analysis, with the 17 
exception of gender, stage and ethnicity (Supplementary Table 1). Females, those with Asian 18 
ethnicity, and those with Carcinoid diagnosis were now slightly less represented in CPES, 19 
and those with high comorbidity scores or increasing stage were more represented in CPES. 20 
3.3 Clinical service and treatment features 21 
Recorded discussion at the MDT was not associated with CPES inclusion, although patients 22 
who were assessed by a LCNS or had a LCNS present when they received their diagnosis 23 
were 25% more likely to be included in CPES than those without these service factors 24 
(OR:1.25; 95% CI=1.18-1.32) (Table 2). Among those assessed by LCNS, the place of 25 
12 
 
assessment or whether they were assessed before or after their diagnosis was not associated 1 
with their odds of being in CPES. 2 
Having received anti-cancer treatment was the strongest factor associated with being included 3 
in CPES. Compared with 56% of people receiving treatment in the whole NLCA population, 4 
96% of people included in CPES had received some combination of radiotherapy, 5 
chemotherapy or surgery; the odds of inclusion in CPES after adjusting for sociodemographic 6 
and clinical features were 10 times higher for those receiving treatment compared with no 7 
anti-cancer treatment (OR=10.26; 95% CI=9.37-11.23 for any treatment). Patients receiving 8 
chemotherapy had the highest odds of being in CPES, followed by surgery and then 9 
radiotherapy. In our analysis restricted to all NLCA patients who survived more than 426 10 
days (Figure 2b) associations between service and treatment features with inclusion in CPES 11 
were similar to the original analysis (Supplementary Table 2). 12 
3.4 Multilevel model including hospital trust level factors 13 
Results from a multilevel model incorporating hospital trust for the LUCADA population of 14 
167,210 lung cancer patients (70% of the NLCA study population) showed little change in 15 
the representativeness across the sociodemographic, clinical, service and treatment features 16 
for inclusion in CPES (Supplementary Table 3), in comparison to the main analyses (Tables 1 17 
and 2). The annual service size of the trust where the patient was first seen was not associated 18 
with inclusion in CPES, however, patients first seen in surgical or chemotherapy trusts were 19 
slightly more likely to be included in CPES, even after adjustment for their individual anti-20 
cancer treatment receipt.  21 
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4. Discussion 1 
4.1 Summary of main findings 2 
Our study of over 240,000 people from the English NLCA showed that those with self-3 
reported information on their clinical experience from CPES had representation across a wide 4 
number of sociodemographic, clinical, health service and anti-cancer treatment groups, 5 
however, balanced representation varied. After accounting for all factors together, we found 6 
CPES under-represented lung cancer patients who were older, from more socioeconomically 7 
deprived groups, had worse performance status, the most advanced stage of cancer, multiple 8 
comorbidities, or were diagnosed via emergency presentation. People diagnosed via the 9 
TWW standard, those with recorded LCNS assessment, and those with SCLC, compared with 10 
NSCLC, were slightly over-represented in CPES.  11 
A clear difference was that 96% of people included in CPES had some form of anti-cancer 12 
treatment (compared with 56% of the overall lung cancer population); they were ten times 13 
more likely to have received anti-cancer treatment compared with people not in CPES. This 14 
likely relates to selection methods reported by CPES that include discharge following a 15 
treatment episode. Those included in CPES were even more likely to have chemotherapy 16 
treatment, for which multiple admissions are required, thus making them even more likely to 17 
have the opportunity to be sampled. Most findings were very similar after excluding lung 18 
cancer patients who died early from the disease, and thus may not have had the chance to 19 
respond to the survey or meet the inclusion criteria for being surveyed. This indicates that, 20 
despite accounting for likely survival bias, people included in CPES are still much more 21 
likely to have received anti-cancer treatment compared with the general lung cancer 22 
population. We also demonstrated that CPES includes patients across the sociodemographic 23 
and clinical spectrum, supporting its utility for research and service planning. However, 24 
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under-representation of socioeconomically deprived groups and certain ethnic minorities 1 
must be considered in the context of implementing changes based on its findings. 2 
4.2 Strengths and limitations of the study 3 
This is the first study to use linked patient level CPES responses and NCRAS records to 4 
assess cancer-specific representation within the survey, demonstrating the strengths of 5 
individual patient linkage across national data sources. Our findings support studies that have 6 
shown age and deprivation as factors influencing recruitment in patient experience surveys 7 
[16, 22]. By linking CPES with the NLCA cancer registry, HES hospital information, IMD 8 
socioeconomic deprivation and ONS deaths, we have been able to study multiple patient and 9 
NHS service characteristics in a large national sample that has provided considerable power. 10 
Our methods demonstrate that this could also be used for advancing patient experience 11 
research in other cancer types. Two UK studies have assessed response rates and method of 12 
response (postal versus online) to CPES [16, 23]. Although broad socio-demographics of 13 
CPES responders were compared with those sampled for all cancers [16], this has not been 14 
able to tell us if their cancer pathway is broadly representative of the whole cancer 15 
population, or if findings are applicable to specific cancer sites which vary widely in patient 16 
populations and clinical care models. Our study was the first to assess the likelihood of 17 
people with a specific incident cancer diagnosis in the population being included in CPES 18 
across the cancer pathway, and we identified under-representation of some important groups. 19 
 20 
The opportunity to be selected as eligible for CPES and respond to the CPES questionnaire 21 
will be influenced by survival time, with a natural bias towards excluding those who die 22 
sooner following their lung cancer diagnosis, which is evident from our results. We made 23 
efforts to account for this selection bias by conducting a sensitivity analysis limiting to 24 
patients who had survived more than 426 days (the 75th quartile of survival for people 25 
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surveyed in CPES), which provided further insight to CPES representativeness for this group. 1 
Although post-sampling mortality is more evident in cancers with poor prognosis [16], such 2 
as lung cancer, our findings from the restricted analysis indicate lack of representation was 3 
more likely to be due to non-response and frequency of hospital use rather than post-sampling 4 
mortality. Variation in response has been reported for different groups of patients, with more 5 
socioeconomically deprived groups and people from ethnic minority backgrounds reporting 6 
to be less likely to respond to such surveys, and responding with less positive experience of 7 
cancer care [24-28]. It is possible that the variation reported may reflect different health, 8 
emotional and support needs of different groups of people with lung cancer. Older, more 9 
socioeconomically deprived people and those diagnosed through emergency presentation 10 
may be less likely to respond to surveys about their experience due to the overall severity of 11 
their health [29]. Alternatively, these groups may have less positive experiences of healthcare 12 
and may be less motivated to respond to CPES with those responding being more critical of 13 
their care [30, 31]. Furthermore, due to the severity of the disease in these groups, they may 14 
be more likely to be admitted to hospice care rather than hospitals and may thus have less 15 
chance of being sampled in CPES.  16 
People who were assessed by a LCNS may have had positive experiences of healthcare 17 
providing more motivation to respond to CPES, or this could reflect people’s more frequent 18 
hospital contact for treatment during which they had LCNS assessment, and thus higher 19 
likelihood of being included in CPES sampling. The positive association between anti-cancer 20 
treatment and the likelihood of being surveyed in CPES is likely explained by more frequent 21 
hospital use and the bias introduced through methodology of hospitals providing discharged 22 
patient lists as the initial step of inclusion for survey recruitment. 23 
4.3 Implication for practice and policy 24 
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We provide estimates of the degree of under-representation in lung cancer patient experience 1 
according to clinical characteristics, age, socioeconomic deprivation and ethnicity, which can 2 
contribute to planning clinical service modifications. We have also shown that CPES largely 3 
represents people with lung cancer who receive anti-cancer treatment, most notably 4 
chemotherapy. In the recent national audit of lung cancer outcomes, 35% of people did not 5 
receive anti-cancer treatment [32], highlighting a need for lung cancer PROMs to also be 6 
representative of these individuals. The design of any PROMS for lung cancer would need to 7 
take short average survival into account and ensure sampling methods were designed to 8 
capture people soon after diagnosis in order to be representative. We advise that it is 9 
important to have patients’ specific treatment types and pathways, available through data 10 
linkage, in order to most appropriately interpret individual patient experience responses in 11 
CPES for use in transforming services. 12 
Our study also supports the continuing emphasis on issues associated with the sampling 13 
methods of CPES. Almost half of people with lung cancer nationally do not receive anti-14 
cancer treatment, and thus CPES does not represent almost half of the national lung cancer 15 
service. It is not the intention of this paper to canvas this debate, but to note that the notion of 16 
a “one size fit all” method of recruitment is not straightforward. Policy makers need to be 17 
aware of the under-representatives of certain groups of lung cancer in CPES. We recommend 18 
modifications to survey methods be considered for cancers with poor prognosis, such as 19 
sending out invitations shortly after discharge or by other means that capture people not 20 
undergoing intensive anti-cancer treatment pathways. Although this may add additional cost 21 
to patient experience surveys, its cost-effectiveness needs to be evaluated. National surveys 22 
are expensive undertaking and should thus strive to ensure they are representative of the 23 
source population to influence policy. In trying to improve the quality of NHS services, data 24 
to support such improvement needs to be of great quality [33]. CPES demonstrates huge 25 
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potential in assessing how people receiving different types of lung cancer treatment may have 1 
different experiences of care and exploring their how their healthcare experience may relate 2 
to their longer-term health outcomes. Further study can assess whether experiences of cancer 3 
treatment decisions are associated with anti-cancer treatments received, informing strategies 4 
to increase rates of active treatment, or whether interactions with health service staff are 5 
associated with rates of unplanned hospital attendances, informing safe staffing policies and 6 
financial impact.  7 
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Abstract  2 
Word count = 255 (/300) 3 
Objectives: Healthcare systems increasingly recognise the importance of service users’ 4 
perspectives for improving care organisation and delivery. The English Cancer Patient 5 
Experience Survey (CPES) is carried out annually, however, its representativeness within 6 
cancer types is unknown. We have explored if the CPES results are representative of people 7 
with lung cancer. 8 
Materials and methods: We linked cancer registry data across multiple sources to assess 9 
how CPES represents sociodemographic and clinical characteristics of the National Lung 10 
Cancer Audit population, accounting for post-sampling mortality bias. Multivariable logistic 11 
regression was used to compare people included and not included in CPES. 12 
Results: Of 240,375 people diagnosed (2009-2015), 15,967 (7%) were included in CPES. 13 
Gender and ethnicity were reasonably represented, as were sociodemographic and clinical 14 
groupings, although more received anti-cancer treatment (96% of CPES respondents vs. 56% 15 
of patients nationally; adjusted odds ratio=10.3, 95% confidence interval 9.4-11.2 for any 16 
anti-cancer treatment) with chemotherapy most over-represented, followed by surgery and 17 
then radiotherapy. CPES under-represented older, more socioeconomically deprived, and 18 
certain clinical groups, including those with worse performance status, multiple 19 
comorbidities, and diagnosis via emergency presentation. 20 
Conclusion: CPES includes patients across the sociodemographic and clinical spectrum 21 
indicating its value for research and service planning. Unbalanced representation of incident 22 
lung cancer cases is a limitation that must be considered in context of using CPES findings to 23 
implement service changes. Although half the national lung cancer population who received 24 
no anti-cancer treatment do not have their experiences represented, the strength of this dataset 25 
is in providing detailed comparisons of patient experiences across different treatment groups.  26 
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1. Introduction 1 
Survival after diagnosis of lung cancer appears to be lower in the UK compared with other 2 
western and European countries, despite recent improvements [1, 2]. Inequalities in the 3 
receipt of anti-cancer treatment have been reported with effective treatment under-utilised 4 
and uptake of active treatment lower in the UK compared with Scandinavian and North 5 
American countries who have better survival [3-6].  6 
Recommendations have been made by the National Institute of Health and Care Excellence to 7 
improve the quality of cancer care in England including the training of specialist cancer 8 
nurses to help identify the needs of people diagnosed with cancer and provide support 9 
throughout the cancer pathway, and involving people in decisions that shape or reshape their 10 
own cancer care including anti-cancer treatment options [7]. There has been significant 11 
investment of resource in surveys measuring patient experience to provide information on the 12 
quality of healthcare directly from the service users’ point of view [8]. The National Lung 13 
Cancer Audit (NLCA) is now a leading national audit and one of the largest and most 14 
detailed on lung cancer internationally, however it lacks a programme for patient reported 15 
outcome or experience measures. 16 
For healthcare service providers, feedback from patient experience surveys helps to identify 17 
where cancer services can focus efforts to improve care [9, 10]. For service users, this helps 18 
in making choices about their care and for quality assurance. The English National Cancer 19 
Patient Experience Survey (CPES) was commissioned by the Department of Health for this 20 
purpose and is carried out annually by Quality Health. Feedback from similar patient 21 
experience surveys has been successful in informing healthcare service quality in outpatient 22 
departments and patient-doctor interaction in countries such as Australia, Finland and the 23 
USA [11-13]. For CPES to achieve its purpose, it is important to understand how patients 24 
responding to the survey represent people diagnosed with lung cancer in England.  It 25 
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currently obtains responses from over 65,000 people with cancer each year, approximately 1 
6% of whom have lung cancer; this representation relative to the incidence of lung cancer is 2 
lower than for many other tumour sites, particularly breast cancer [14, 15], which may 3 
partially reflect CPES’s sampling frame of selecting people recently discharged from hospital 4 
treatment episodes.  Post-sampling mortality and sociodemographic variation in survey 5 
response patterns in CPES has been assessed across all cancer types [16]. Assessment of how 6 
CPES respondents are representative of the whole incident cancer population, however, has 7 
not been conducted, which is arguably important for the application of CPES in changing 8 
cancer services that serve all people with cancer. To do this, a comprehensive assessment for 9 
each cancer type is required, that includes detailed comparisons between individuals’ clinical 10 
and treatment pathways as well as their sociodemographic characteristics. This opportunity 11 
has only recently arisen through the individual patient linkage of CPES to national cancer 12 
registry data. 13 
We used national cancer registry data (from the NLCA) linked across multiple sources 14 
including route to diagnosis, anti-cancer treatments and long-term follow up, to assess how 15 
people with incident diagnoses of lung cancer included in CPES represent the 16 
sociodemographic, clinical, treatment characteristics and survival of the whole incident lung 17 
cancer population in England. 18 
  19 
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2. Materials and methods 1 
2.1 Study population and data sources  2 
Information on all people in England with a new primary diagnosis of lung cancer 3 
(International Classification of Diseases (ICD-10) codes C34*) between 2009 and 2015 was 4 
obtained from the National Cancer Registration and Analysis Service (NCRAS) run by Public 5 
Health England (PHE). NCRAS forms the most complete source of information on all people 6 
diagnosed with incident cancer by obtaining information from across the National Health 7 
Service (NHS), which covers 98-99% of all hospital activity in England. The NLCA 8 
comprises those individuals in NCRAS with a lung cancer diagnosis. We also accessed linked 9 
survey results of those included in at least one wave of the national CPES between 2010 and 10 
2015 (waves 1:2010, 2:2011, 3:2012, 4:2013, 5:2015). 11 
2.1.1 The National Cancer Patient Experience Survey (CPES) 12 
CPES collects self-reported information from people diagnosed with cancer about their 13 
experience of primary care pre-diagnosis, ongoing clinical management and longer-term 14 
support. It includes over 70 questions across 12 different domains. The survey is sent to all 15 
people in England aged 16 years and older with a primary diagnosis of cancer (identified 16 
using ICD-10 codes, excluding C44-other malignant neoplasms of the skin and C84-17 
peripheral and cutaneous T-cell lymphomas) who have been admitted as an inpatient or day-18 
case to hospital in relation to their cancer and discharged within the specified survey period 19 
each year (usually a three-month window, with some variation across waves). People are sent 20 
the survey by post, with two reminders for non-respondents; there are also options to 21 
complete wave 5 online or via telephone. All survey questions have undergone cognitive 22 
interview testing on samples of people with different types of cancer in different English 23 
regions [17].  24 
2.1.2 NCRAS data linkages 25 
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For all lung cancer patients we used information on age, gender, ethnicity, lung cancer type, 1 
stage at diagnosis, and route to diagnosis from their NCRAS record. Lung cancer 2 
morphology was defined using recorded Systematised Nomenclature of Medicine 3 
(SNOMED) codes. People whose SNOMED codes were missing or coded as unknown were 4 
classified as non-small-cell lung cancer (NSCLC) based on the method used by the NLCA to 5 
define lung cancer [3]. 6 
NCRAS records for NLCA patients were also linked at individual-level to Hospital Episode 7 
Statistics (HES) data which included all hospital inpatient, outpatient and emergency 8 
admissions. We used all relevant ICD-coded conditions in these admissions up to the lung 9 
cancer diagnosis to calculate a comorbidity score for each patient (Charlson Index) [18]. To 10 
build patient profiles of surgical, radiotherapy and chemotherapy treatments, we used 11 
admissions for surgery, radiotherapy or chemotherapy related to their lung cancer in 12 
conjunction with individual linked treatment databases, the National Radiotherapy Dataset 13 
and Systemic Anti-cancer Therapy dataset, and treatments recorded in the core cancer 14 
registry data [19, 20]. In HES data, we identified Office of Population Census and Survey 15 
Classification of Intervention version 4 codes corresponding to surgical, chemotherapy and 16 
radiotherapy treatment. In line with methods used by the NLCA to define anti-cancer 17 
treatment related to lung cancer, we define surgical resection of lung cancer within a 18 
timeframe of 1 month before to 6 months after diagnosis of lung cancer, and relevant 19 
chemotherapy or radiotherapy rounds as 1 month before to 9 months after diagnosis [3]. 20 
Survival time was calculated from their diagnosis date to their date of death obtained from 21 
the Office of National Statistics (ONS) or follow-up was truncated at the date of ONS cross-22 
check for death (28/01/2018). Household socioeconomic deprivation was measured as 23 
quintiles of the Index of Multiple Deprivation based on national census data and was linked 24 
to individuals’ records based on their home postcode. 25 
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Although we had the NCRAS record across our whole study period, we also used pre-2015 1 
NLCA data that was provided through a bespoke data collection system, called Lung Cancer 2 
Audit Data (LUCADA). Data entry in LUCADA was non-mandatory and showed some 3 
selection bias [21], however, they were entered by the multidisciplinary team (MDT) in NHS 4 
hospitals and included more detailed information on patient pathway including hospital-trust 5 
first seen, timing and method of Lung Cancer Nurse Specialist (LCNS) assessments and 6 
performance status (PS). This is the first time all of these linkages had been done collectively. 7 
PHE’s Office for Data Release (PHE ODR) conducted all individual matching procedures for 8 
people diagnosed with lung cancer from the core cancer registry to CPES and other data 9 
sources using bespoke algorithms that included NHS number and tumour type, as described 10 
on their website (www.ncin.org.uk). 11 
2.2 Statistical analysis 12 
Data management and analyses were carried out using Stata 15 (StataCorp, College Station, 13 
TX, USA). We compared proportions of key variables, including age, gender, PS, lung 14 
cancer stage, anti-cancer treatment and clinical service factors between people in CPES and 15 
the whole NLCA population from NCRAS. We used multivariate logistic regression to 16 
calculate odds ratios (OR) to quantify the extent to which being in CPES varied by these key 17 
variables. For the subset of patients with a LUCADA record we repeated the main analyses 18 
using a multilevel logistic regression model fitting patient and hospital level factors, enabling 19 
us to assess whether trust size (number of new lung cancer patients seen annually) or trust 20 
treatment specialty were associated with inclusion in CPES. 21 
We compared survival of those included and not included in CPES using the Kaplan–Meier 22 
method. To assess the potential effects of survival bias on our overall analyses, we conducted 23 
a subgroup analysis restricting the NCRAS study population to people who survived more 24 
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than 426 days after diagnosis, which was the 75th quartile of survival for people surveyed in 1 
CPES.  2 
10 
 
3. Results 1 
3.1 Study population 2 
The flow diagram (Figure 1) demonstrates how the study population was derived. From the 3 
whole NLCA population, we included only those with one primary lung cancer diagnosis (not 4 
multiple tumours) (N=244,957). We excluded individuals diagnosed before age 18 years or 5 
diagnosed upon or after their death (death certificate cases). From an initial 18,023 6 
individuals with linked CPES questionnaires, we excluded 698 individuals whose CPES 7 
records were likely to be unrelated to their lung cancer diagnosis. The final study population 8 
was 240,375 people with primary lung cancer diagnosed between 2009 and 2015, 15,967 9 
(6.6%) of whom had a linked CPES questionnaire. Of those in CPES; 2,761(17.9%), 3,327 10 
(20.8%), 3,353 (21.0%), 3,185(20.0%) and 3,341 (20.9%) were from waves 1 to 5, 11 
respectively. Seventy percent (167,210) of the 240,375 people had linked LUCADA 12 
information. 13 
3.2 Sociodemographic and clinical features 14 
Table 1 shows a multivariate logistic regression model assessing the odds of being included 15 
in CPES according to various characteristics. Inclusion increased over time, apart from a dip 16 
for people diagnosed in 2014 because CPES was not conducted that year. Overall, patients 17 
included in CPES had representation across every sociodemographic and clinical grouping, 18 
however, representativeness varied by feature and those in CPES were less likely to have 19 
missing information for stage, performance status, ethnicity and route to diagnosis. Women 20 
had a small increase in adjusted odds of being included in CPES compared with men. 21 
Adjusted odds of inclusion in CPES generally decreased with increasing age, PS, 22 
comorbidities and socioeconomic deprivation. Patients with a PS of 1-4, clinically recorded 23 
in their LUCADA record close to the time they were initially diagnosed, were less likely to 24 
be included in CPES compared with those recorded as PS0, clinically considered as fully 25 
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functional and asymptomatic (OR=0.79; 95% CI=0.39-0.16 for PS1-4 collectively compared 1 
with PS0). Compared with stage Sg1A, stages SgIB-IIIA were considerably more likely to be 2 
represented in CPES, whereas SgIV and missing stage were less likely to be represented. 3 
Ethnicity was not associated with the likelihood of inclusion in CPES, however, people in 4 
CPES were more likely to have complete information on ethnicity. All lung cancer types 5 
were included, with a small increase in representativeness of SCLC compared with NSCLC. 6 
Being diagnosed with lung cancer through the Two Week Wait NHS standard (an urgent 7 
referral requiring the person to be seen by a specialist within 14 days) was associated with a 8 
greater adjusted odds of inclusion in CPES, (OR=1.26; 95% CI=1.21-1.32), whilst 9 
emergency presentation was associated with a lower odds of inclusion (OR=0.52; 95% 10 
CI=0.49-0.55) compared with primary care referral. 11 
People included in CPES had considerably longer survival from diagnosis; (median survival 12 
was 158 days for those not in CPES and 774 days for those included in CPES (Figure 2a). 13 
When the analysis was restricted to all NLCA patients who survived more than 426 days, the 14 
75
th
 quartile of survival for those in CPES, this did not result in the CPES population being 15 
more evenly representative despite similar survival (Figure 2b). Results across 16 
sociodemographic and clinical features were very similar to the original analysis, with the 17 
exception of gender, stage and ethnicity (Supplementary Table 1). Females, those with Asian 18 
ethnicity, and those with Carcinoid diagnosis were now slightly less represented in CPES, 19 
and those with high comorbidity scores or increasing stage were more represented in CPES. 20 
3.3 Clinical service and treatment features 21 
Recorded discussion at the MDT was not associated with CPES inclusion, although patients 22 
who were assessed by a LCNS or had a LCNS present when they received their diagnosis 23 
were 25% more likely to be included in CPES than those without these service factors 24 
(OR:1.25; 95% CI=1.18-1.32) (Table 2). Among those assessed by LCNS, the place of 25 
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assessment or whether they were assessed before or after their diagnosis was not associated 1 
with their odds of being in CPES. 2 
Having received anti-cancer treatment was the strongest factor associated with being included 3 
in CPES. Compared with 56% of people receiving treatment in the whole NLCA population, 4 
96% of people included in CPES had received some combination of radiotherapy, 5 
chemotherapy or surgery; the odds of inclusion in CPES after adjusting for sociodemographic 6 
and clinical features were 10 times higher for those receiving treatment compared with no 7 
anti-cancer treatment (OR=10.26; 95% CI=9.37-11.23 for any treatment). Patients receiving 8 
chemotherapy had the highest odds of being in CPES, followed by surgery and then 9 
radiotherapy. In our analysis restricted to all NLCA patients who survived more than 426 10 
days (Figure 2b) associations between service and treatment features with inclusion in CPES 11 
were similar to the original analysis (Supplementary Table 2). 12 
3.4 Multilevel model including hospital trust level factors 13 
Results from a multilevel model incorporating hospital trust for the LUCADA population of 14 
167,210 lung cancer patients (70% of the NLCA study population) showed little change in 15 
the representativeness across the sociodemographic, clinical, service and treatment features 16 
for inclusion in CPES (Supplementary Table 3), in comparison to the main analyses (Tables 1 17 
and 2). The annual service size of the trust where the patient was first seen was not associated 18 
with inclusion in CPES, however, patients first seen in surgical or chemotherapy trusts were 19 
slightly more likely to be included in CPES, even after adjustment for their individual anti-20 
cancer treatment receipt.  21 
13 
 
4. Discussion 1 
4.1 Summary of main findings 2 
Our study of over 240,000 people from the English NLCA showed that those with self-3 
reported information on their clinical experience from CPES had representation across a wide 4 
number of sociodemographic, clinical, health service and anti-cancer treatment groups, 5 
however, balanced representation varied. After accounting for all factors together, we found 6 
CPES under-represented lung cancer patients who were older, from more socioeconomically 7 
deprived groups, had worse performance status, the most advanced stage of cancer, multiple 8 
comorbidities, or were diagnosed via emergency presentation. People diagnosed via the 9 
TWW standard, those with recorded LCNS assessment, and those with SCLC, compared with 10 
NSCLC, were slightly over-represented in CPES.  11 
A clear difference was that 96% of people included in CPES had some form of anti-cancer 12 
treatment (compared with 56% of the overall lung cancer population); they were ten times 13 
more likely to have received anti-cancer treatment compared with people not in CPES. This 14 
likely relates to selection methods reported by CPES that include discharge following a 15 
treatment episode. Those included in CPES were even more likely to have chemotherapy 16 
treatment, for which multiple admissions are required, thus making them even more likely to 17 
have the opportunity to be sampled. Most findings were very similar after excluding lung 18 
cancer patients who died early from the disease, and thus may not have had the chance to 19 
respond to the survey or meet the inclusion criteria for being surveyed. This indicates that, 20 
despite accounting for likely survival bias, people included in CPES are still much more 21 
likely to have received anti-cancer treatment compared with the general lung cancer 22 
population. We also demonstrated that CPES includes patients across the sociodemographic 23 
and clinical spectrum, supporting its utility for research and service planning. However, 24 
14 
 
under-representation of socioeconomically deprived groups and certain ethnic minorities 1 
must be considered in the context of implementing changes based on its findings. 2 
4.2 Strengths and limitations of the study 3 
This is the first study to use linked patient level CPES responses and NCRAS records to 4 
assess cancer-specific representation within the survey, demonstrating the strengths of 5 
individual patient linkage across national data sources. Our findings support studies that have 6 
shown age and deprivation as factors influencing recruitment in patient experience surveys 7 
[16, 22]. By linking CPES with the NLCA cancer registry, HES hospital information, IMD 8 
socioeconomic deprivation and ONS deaths, we have been able to study multiple patient and 9 
NHS service characteristics in a large national sample that has provided considerable power. 10 
Our methods demonstrate that this could also be used for advancing patient experience 11 
research in other cancer types. Two UK studies have assessed response rates and method of 12 
response (postal versus online) to CPES [16, 23]. Although broad socio-demographics of 13 
CPES responders were compared with those sampled for all cancers [16], this has not been 14 
able to tell us if their cancer pathway is broadly representative of the whole cancer 15 
population, or if findings are applicable to specific cancer sites which vary widely in patient 16 
populations and clinical care models. Our study was the first to assess the likelihood of 17 
people with a specific incident cancer diagnosis in the population being included in CPES 18 
across the cancer pathway, and we identified under-representation of some important groups. 19 
 20 
The opportunity to be selected as eligible for CPES and respond to the CPES questionnaire 21 
will be influenced by survival time, with a natural bias towards excluding those who die 22 
sooner following their lung cancer diagnosis, which is evident from our results. We made 23 
efforts to account for this selection bias by conducting a sensitivity analysis limiting to 24 
patients who had survived more than 426 days (the 75th quartile of survival for people 25 
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surveyed in CPES), which provided further insight to CPES representativeness for this group. 1 
Although post-sampling mortality is more evident in cancers with poor prognosis [16], such 2 
as lung cancer, our findings from the restricted analysis indicate lack of representation was 3 
more likely to be due to non-response and frequency of hospital use rather than post-sampling 4 
mortality. Variation in response has been reported for different groups of patients, with more 5 
socioeconomically deprived groups and people from ethnic minority backgrounds reporting 6 
to be less likely to respond to such surveys, and responding with less positive experience of 7 
cancer care [24-28]. It is possible that the variation reported may reflect different health, 8 
emotional and support needs of different groups of people with lung cancer. Older, more 9 
socioeconomically deprived people and those diagnosed through emergency presentation 10 
may be less likely to respond to surveys about their experience due to the overall severity of 11 
their health [29]. Alternatively, these groups may have less positive experiences of healthcare 12 
and may be less motivated to respond to CPES with those responding being more critical of 13 
their care [30, 31]. Furthermore, due to the severity of the disease in these groups, they may 14 
be more likely to be admitted to hospice care rather than hospitals and may thus have less 15 
chance of being sampled in CPES.  16 
People who were assessed by a LCNS may have had positive experiences of healthcare 17 
providing more motivation to respond to CPES, or this could reflect people’s more frequent 18 
hospital contact for treatment during which they had LCNS assessment, and thus higher 19 
likelihood of being included in CPES sampling. The positive association between anti-cancer 20 
treatment and the likelihood of being surveyed in CPES is likely explained by more frequent 21 
hospital use and the bias introduced through methodology of hospitals providing discharged 22 
patient lists as the initial step of inclusion for survey recruitment. 23 
4.3 Implication for practice and policy 24 
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We provide estimates of the degree of under-representation in lung cancer patient experience 1 
according to clinical characteristics, age, socioeconomic deprivation and ethnicity, which can 2 
contribute to planning clinical service modifications. We have also shown that CPES largely 3 
represents people with lung cancer who receive anti-cancer treatment, most notably 4 
chemotherapy. In the recent national audit of lung cancer outcomes, 35% of people did not 5 
receive anti-cancer treatment [32], highlighting a need for lung cancer PROMs to also be 6 
representative of these individuals. The design of any PROMS for lung cancer would need to 7 
take short average survival into account and ensure sampling methods were designed to 8 
capture people soon after diagnosis in order to be representative. We advise that it is 9 
important to have patients’ specific treatment types and pathways, available through data 10 
linkage, in order to most appropriately interpret individual patient experience responses in 11 
CPES for use in transforming services. 12 
Our study also supports the continuing emphasis on issues associated with the sampling 13 
methods of CPES. Almost half of people with lung cancer nationally do not receive anti-14 
cancer treatment, and thus CPES does not represent almost half of the national lung cancer 15 
service. It is not the intention of this paper to canvas this debate, but to note that the notion of 16 
a “one size fit all” method of recruitment is not straightforward. Policy makers need to be 17 
aware of the under-representatives of certain groups of lung cancer in CPES. We recommend 18 
modifications to survey methods be considered for cancers with poor prognosis, such as 19 
sending out invitations shortly after discharge or by other means that capture people not 20 
undergoing intensive anti-cancer treatment pathways. Although this may add additional cost 21 
to patient experience surveys, its cost-effectiveness needs to be evaluated. National surveys 22 
are expensive undertaking and should thus strive to ensure they are representative of the 23 
source population to influence policy. In trying to improve the quality of NHS services, data 24 
to support such improvement needs to be of great quality [33]. CPES demonstrates huge 25 
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potential in assessing how people receiving different types of lung cancer treatment may have 1 
different experiences of care and exploring their how their healthcare experience may relate 2 
to their longer-term health outcomes. Further study can assess whether experiences of cancer 3 
treatment decisions are associated with anti-cancer treatments received, informing strategies 4 
to increase rates of active treatment, or whether interactions with health service staff are 5 
associated with rates of unplanned hospital attendances, informing safe staffing policies and 6 
financial impact.  7 
18 
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Figure 1: Flow chart of study population derivation: people with primary lung cancers in the English national cancer 
register  
CPES: Cancer Patient Experience Survey; NLCA: National Lung Cancer Audit; LUCADA: Lung Cancer Audit Data 
 
Number of people with one primary 
lung cancer tumour diagnosed 
between 2009 and 2015 in NLCA 
N=244,957 
Number of people after applying 
criteria 
N=240,420 
Exclusion criteria:  
Date of diagnosis >= date of death  
(n=4,517) 
Age at diagnosis < 18 years (n=20) 
Number of records after linking with 
CPES 
N=241,073 
Exclusion criteria for people surveyed in CPES: 
 
 
Date of death < recruitment start date (first day when questionnaire 
sent out) (n=3) 
 
Date of diagnosis > recruitment end date (last day when questionnaire 
sent out) (n=18) 
 
Year of diagnosis > CPES recruitment year (n=24) 
 
For individuals with multiple responses across waves, waves further 
away from year of diagnosis excluded (n=572) 
 
For individuals with responses to >1 questionnaire in the same wave, 
less complete questionnaires excluded (n=81) 
Final NLCA study population 
N=240,375 












Figure 2. Kaplan-Meier survival curves of survival from lung cancer diagnosis comparing people included and not 
included in CPES. 





Table 1: Comparison of baseline and clinical characteristics for all lung cancer patients in NLCA with those in CPES 
Characteristic 
Total number of 
people (N=240,375) 
n (%) 
Number of people 
in CPES (N=15,967) 
n (%) 
Unadjusted OR of 
being surveyed 
(95% CI) 
Adjusted OR of 







Year of diagnosis        
 
  
2009 31893(13.3) 1490(9.3) 1 1 
 
  
2010 32594(13.6) 1790(11.2) 1.19(1.10  -  1.27) 1.09(1.01 - 1.17) 
 
  
2011 33671(14.0) 3212(20.1) 2.15(2.02  -  2.29) 1.93(1.80 - 2.07) 
 
  
2012 34714(14.4) 3302(20.7) 2.14(2.01  -  2.28) 1.60(1.49 - 1.72) 
 
  
2013 35041(14.6) 3028(19.0) 1.93(1.81  -  2.06) 1.48(1.38 - 1.59) 
 
  
2014 36165(15.1) 631(4.0) 0.36(0.33  -  0.40) 0.34(0.31 - 0.38) 
 
  
2015 36297(15.1) 2514(15.7) 1.52(1.42  -  1.62) 2.08(1.88 - 2.30) <0.001 <0.001 
Gender        
 
  
Male 130804(54.6) 8561(53.6) 1 1 
 
  
Female 109571(45.5) 7406(46.4) 1.04(1.00  -  1.07) 1.06(1.02 - 1.09) 0.001   
Age (years)        
 
  
<65 56737(23.6) 5442(34.1) 1 1 
 
  
65-80 126872(52.8) 9394(58.8) 0.75(0.73  -  0.78) 0.84(0.81 - 0.87) 
 
  
>80 56766(23.6) 1131(7.1) 0.19(0.18  -  0.20) 0.31(0.29 - 0.33) <0.001 <0.001 
Stage        
 
  
SgIA 16902(7.0) 1418(8.9) 1 1 
 
  
SgIB 13745(5.7) 1466(9.2) 1.30(1.21  -  1.41) 1.29(1.19 - 1.40) 
 
  
SgIIA 7569(3.2) 1076(6.7) 1.81(1.66  -  1.97) 1.68(1.54 - 1.84) 
 
  
SgIIB 7259(3.0) 854(5.4) 1.46(1.33  -  1.59) 1.49(1.36 - 1.64) 
 
  
SgIIIA 25091(10.4) 2783(17.4) 1.36(1.27  -  1.46) 1.34(1.25 - 1.44) 
 
  
SgIIIB 19037(7.9) 1764(11.1) 1.12(1.04  -  1.20) 1.03(0.95 - 1.11) 
 
  
SgIV 102323(42.6) 4843(30.3) 0.54(0.51  -  0.58) 0.69(0.64 - 0.73) <0.001 <0.001 
Missing 48449(20.2) 1763(11.0) 0.41(0.38  -  0.44) 0.69(0.64 - 0.75) 
 
  
Performance status*        
 
  
0 25464(10.6) 4354(27.3) 1 1 
 
  
1 46805(19.5) 5328(33.4) 0.62(0.60  -  0.65) 0.79(0.75 - 0.82) 
 
  
2 27056(11.3) 1304(8.2) 0.25(0.23  -  0.26) 0.39(0.36 - 0.42) 
 
  
3 30491(12.7) 415(2.6) 0.07(0.06  -  0.07) 0.16(0.14 - 0.18) 
 
  
4 8115(3.4) 18(0.1) 0.01(0.01  -  0.02) 0.03(0.02 - 0.05) <0.001 <0.001 
Missing 29279(12.2) 1194(7.5) 0.21(0.19  -  0.22) 0.49(0.45 - 0.52) 
 
  
Ethnicity        
 
  
White 200615(83.5) 14504(90.8) 1 1 
 
  
Black 1772(0.7) 122(0.8) 0.95(0.79  -  1.14) 1.03(0.85 - 1.24) 
 
  
Asian 3018(1.3) 187(1.2) 0.85(0.73  -  0.98) 0.89(0.76 - 1.04) 
 
  
Mixed 442(0.2) 32(0.2) 1.00(0.70  -  1.44) 0.98(0.67 - 1.43) 
 
  
Other 1473(0.6) 102(0.6) 0.95(0.78  -  1.17) 0.95(0.77 - 1.18) 0.275   









1-least deprived 33715(14.0) 2557(16.0) 1 1 
 
  
2 43094(17.9) 3222(20.2) 0.98(0.93  -  1.04) 0.96(0.91 - 1.02) 
 
  
3 47549(19.8) 3297(20.7) 0.91(0.86  -  0.96) 0.90(0.85 - 0.96) 
 
  
4 53048(22.1) 3354(21.0) 0.82(0.78  -  0.87) 0.81(0.77 - 0.86) 
 
  
5-most deprived 62969(26.2) 3537(22.2) 0.73(0.69  -  0.76) 0.70(0.67 - 0.74) <0.001 <0.001 
Comorbidity (Charlson index)        
 
  
0 76055(31.6) 6589(41.3) 1 1 
 
  
1 41235(17.2) 3473(21.8) 0.97(0.93  -  1.01) 1.09(1.04 - 1.14) 
 
  
2-3 39738(16.5) 2428(15.2) 0.69(0.65  -  0.72) 0.93(0.88 - 0.98) 
 
  
4+ 83347(34.7) 3477(21.8) 0.46(0.44  -  0.48) 0.86(0.82 - 0.90) <0.001 <0.001 
Route to diagnosis        
 
  
GP referral 52649(21.9) 4062(25.4) 1 1 
 
  
Emergency presentation 85116(35.4) 2012(12.6) 0.29(0.27  -  0.31) 0.52(0.49 - 0.55) 
 
  
Inpatient elective 4007(1.7) 287(1.8) 0.92(0.81  -  1.04) 0.96(0.84 - 1.09) 
 
  
Other outpatient 26425(11.0) 2161(13.5) 1.07(1.01  -  1.12) 1.00(0.95 - 1.06) 
 
  
TWW 66887(27.8) 7318(45.8) 1.47(1.41  -  1.53) 1.26(1.21 - 1.32) <0.001   
Missing 5291(2.2) 127(0.8) 0.29(0.25  -  0.35) 0.45(0.38 - 0.55) 
 
  
Lung cancer type        
 
  
NSCLC 211265(87.9) 13268(83.1) 1 1 
 
  
Carcinoid 2408(1.0) 273(1.7) 1.91(1.68  -  2.17) 1.09(0.95 - 1.25) 
 
  
SCLC 26702(11.1) 2426(15.2) 1.49(1.43  -  1.56) 1.51(1.44 - 1.59) <0.001   
Abbreviations: CI: confidence interval; CPES: Cancer Patient Experience Survey; GP: general practice; NLCA: National Lung Cancer Audit; NSCLC: 
non-small cell lung cancer; OR: odds ratio; SCLC: small cell lung cancer; TWW: Two-week wait 
Notes: Logistic regression model with ORs adjusted for all other variables in the table. Missing not included in p-values. 
       *Performance status only available for patients in Lung Cancer Audit Data (LUCADA) sub-population (N=167,210) 
        
Table 1 - resubmission following reviewer suggestion
Table 2: Comparison of health service and treatment characteristics for all lung cancer patients in NLCA with those 
included in CPES 
 
Characteristic 
Total number of 
people (N=240,375) 
n (%) 
Number of people 
in CPES (N=15,967) 
n (%) 
Adjusted OR of being 
in CPES (95% CI) p-value Test for trend 
MDT discussion*       
 
  
No 8908(5.3) 423(3.4) 1 
 
  
Yes 158302(94.7) 12190(96.7) 0.97(0.87 - 1.08) 0.549   
 LCNS assessed*       
 
  
No 43614(26.1) 1936(15.4) 1 
 
  
Yes 123596(73.9) 10677(84.7) 1.25(1.18 - 1.32) <0.001   
First LCNS assessment*       
 
  
After diagnosis 92205(74.6) 8046(75.4) 1.00    
Before/at diagnosis 26432(21.4) 2251(21.1) 0.99(0.94-1.04) 0.871   
Missing 4959(4.0) 380(3.6) 0.86(0.77-0.96)    
Place of LCNS assessment*       
 
  
In clinic 80159(64.9) 8126(76.1) 1 
 
  
Home visit 1035(0.8) 82(0.8) 1.06(0.84 - 1.34) 
 
  
Ward visit 23492(19.0) 732(6.9) 0.64(0.59 - 0.70) 
 
  
Telephone 9171(7.4) 941(8.8) 1.07(0.99 - 1.15) 
 
  
Other 2908(2.4) 221(2.1) 0.97(0.84 - 1.13) 0.002   
Missing 6831(5.5) 575(5.4) 0.89(0.81 - 0.98) 
 
  
LCNS present at diagnosis*       
 
  
No  28013(22.7) 1980(18.5) 1 
 
  
Yes 91476(74.0) 8408(78.8) 1.15(1.09 - 1.21) <0.001   




Anti-cancer treatment modality 
(all patients)       
 
  
No treatment 101276(44.1) 537(4.0) 1 
 
  
Surgery 22298(9.7) 2738(20.4) 10.23(9.16 - 11.42) 
 
  
Chemo and radio 36650(16.0) 5680(42.3) 19.64(17.80 - 21.68) 
 
  
Chemotherapy alone 27755(12.1) 3085(23.0) 15.16(13.72 - 16.75) 
 
  
Radiotherapy only 41758(18.2) 1393(10.4) 4.35(3.92 - 4.82) <0.001   
 NSCLC patients only:       
 
  
No treatment 93908(46.7) 496(4.6) 1 
 
  
Surgery 20389(10.1) 2516(23.2) 10.26(9.14 - 11.52) 
 
  
Chemo and radio 25699(12.8) 3750(34.6) 18.03(16.23 - 20.02) 
 
  
Chemotherapy alone 21374(10.6) 2769(25.6) 17.78(16.00 - 19.76) 
 
  
Radiotherapy only 39744(19.8) 1308(12.1) 4.26(3.83 - 4.75) <0.001   
SCLC patients only:       
 
  
No treatment 6956(26.5) 21(0.9) 1 
 
  
Surgery 141(0.5) 9(0.4) 9.80(4.22 - 22.76) 
 
  
Chemo and radio 10,913(41.5) 1921(82.3) 42.21(27.23 - 65.44) 
 
  
Chemotherapy alone 6,310(24.0) 302(12.9) 11.46(7.32 - 17.92) 
 
  
Radiotherapy only 1,959(7.5) 80(3.4) 10.45(6.43 - 16.99) <0.001   
 
Abbreviations: CI: confidence interval; CPES: Cancer Patient Experience Survey; LCNS: lung cancer nurse specialist; MDT: multidisciplinary discussion; 
NLCA: National Lung Cancer Audit; NSCLC: non-small cell lung cancer; OR: odd ratio; SCLC: small cell lung cancer; TWW: Two-week wait 
Notes: Logistic regression model with ORs adjusted for all for gender, age, performance status, stage of cancer at diagnosis, ethnicity, socioeconomic 
deprivation, Charlson Index of comorbidity, route to diagnosis, lung cancer type and year of diagnosis. Missing not included in p-values. 







Supplementary Table 1: Comparison of baseline and clinical characteristics for all lung cancer patients in NLCA with 












Adjusted OR of being 
in CPES (95% CI) p-value Test for trend 





2009 8423(11.5) 1198(10.0) 1 
 
  
2010 8978(12.2) 1241(10.4) 0.89(0.82 - 0.98) 
 
  
2011 9608(13.1) 2279(19.0) 1.74(1.59 - 1.89) 
 
  
2012 10899(14.8) 2409(20.1) 1.45(1.33 - 1.58) 
 
  
2013 11177(15.2) 2273(19.0) 1.35(1.24 - 1.47) 
 
  
2014 11905(16.2) 608(5.1) 0.34(0.30 - 0.38) 
 
  
2015 12510(17.0) 1972(16.5) 1.60(1.43 - 1.81) <0.001 <0.001 





Male 36564(49.8) 6223(51.9) 1 
 
  
Female 36936(50.3) 5757(48.1) 0.94(0.91 - 0.98) 0.006   





<65 21817(29.7) 4186(34.9) 1 
 
  
65-80 40421(55.0) 7040(58.8) 0.93(0.89 - 0.98) 
 
  
>80 11262(15.3) 754(6.3) 0.38(0.35 - 0.42) <0.001 <0.001 





SgIA 13773(18.7) 1359(11.3) 1 
 
  
SgIB 10055(13.7) 1362(11.4) 1.36(1.25 - 1.48) 
 
  
SgIIA 5015(6.8) 972(8.1) 1.93(1.76 - 2.12) 
 
  
SgIIB 3950(5.4) 738(6.2) 1.90(1.71 - 2.10) 
 
  
SgIIIA 10923(14.9) 2204(18.4) 1.97(1.83 - 2.13) 
 
  
SgIIIB 5562(7.6) 1214(10.1) 1.98(1.81 - 2.17) 
 
  
SgIV 13801(18.8) 2858(23.9) 2.08(1.93 - 2.24) <0.001 <0.001 
Missing 10421(14.2) 1273(10.6) 1.39(1.27 - 1.52) 
 
  





0 14507(19.7) 3512(29.3) 1 
 
  
1 19569(26.6) 3835(32.0) 0.87(0.82 - 0.92) 
 
  
2 5830(7.9) 781(6.5) 0.58(0.53 - 0.63) 
 
  
3 5102(6.9) 286(2.4) 0.39(0.34 - 0.44) 
 
  
4 324(0.4) 8(0.1) 0.12(0.06 - 0.25) <0.001 <0.001 
Missing 7731(10.5) 937(7.8) 0.71(0.66 - 0.77) 
 
  





White 64193(87.3) 10937(91.3) 1 
 
  
Black 701(1.0) 101(0.8) 0.88(0.71 - 1.10) 
 
  
Asian 1277(1.7) 156(1.3) 0.70(0.59 - 0.83) 
 
  
Mixed 168(0.2) 22(0.2) 0.77(0.48 - 1.22) 
 
  
Other 567(0.8) 87(0.7) 0.86(0.68 - 1.09) <0.001   
Missing 6594(9.0) 677(5.7) 0.62(0.57 - 0.67) 
 
  





1-least deprived 11062(15.1) 1949(16.3) 1.00 
 
  
2 13504(18.4) 2376(19.8) 0.97(0.91 - 1.04) 
 
  
3 14380(19.6) 2488(20.8) 0.95(0.89 - 1.02) 
 
  
4 15863(21.6) 2521(21.0) 0.85(0.80 - 0.91) 
 
  
5-most deprived 18691(25.4) 2646(22.1) 0.74(0.69 - 0.79) <0.001 <0.001 





0 29457(40.1) 5033(42.0) 1 
 
  
1 16070(21.9) 2682(22.4) 1.10(1.04 - 1.16) 
 
  
2-3 14054(19.1) 1912(16.0) 1.00(0.94 - 1.06) 
 
  
4+ 13919(18.9) 2353(19.6) 1.12(1.05 - 1.18) 0.002 <0.001 





GP referral 21360(29.1) 3174(26.5) 1 
 
  
Emergency presentation 10866(14.8) 1322(11.0) 0.86(0.80 - 0.92) 
 
  
Inpatient elective 1147(1.6) 194(1.6) 1.04(0.88 - 1.23) 
 
  
Other outpatient 12198(16.6) 1749(14.6) 0.97(0.90 - 1.03) 
 
  
TWW 26236(35.7) 5448(45.5) 1.28(1.22 - 1.35) 
 
  
Missing 1693(2.3) 93(0.8) 0.43(0.34 - 0.53) <0.001   





NSCLC 65450(89.1) 10301(86.0) 1 
 
  
Carcinoid 2234(3.0) 267(2.2) 0.86(0.75 - 0.98) 
 
  
SCLC 5816(7.9) 1412(11.8) 1.38(1.29 - 1.48) <0.001   
 
Abbreviations: CI: confidence interval; CPES: Cancer Patient Experience Survey; GP: general practice; NLCA: National Lung Cancer Audit;  
NSCLC: non-small cell lung cancer; OR: odds ratio; SCLC: small cell lung cancer; TWW: Two-week wait 
Notes: Logistic regression model with ORs adjusted for all other variables in the table. Missing not included in p-values.       
*Performance status only available for patients in Lung Cancer Audit Data (LUCADA) sub-population (N=53,063)       
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Supplementary Table 2: Comparison of health service and treatment characteristics for all lung cancer patients in NLCA 
with those included in CPES who survived more than 426 days after diagnosis 
 
Characteristic 
Total number of 
people(N=73,500) 
n (%) 
Number of people 
in CPES(N=11,980) 
n (%) 
Adjusted OR of being 
in CPES(95% CI) p-value 
Test for 
trend 
MDT discussion*       
 
  
No 2888(5.4) 335(3.6) 1.00 
 
  
Yes 50175(94.6) 9024(96.4) 1.03(0.91 - 1.18) 0.603   
Assessed by LCNS*       
 
  
No 11713(22.1) 1513(16.2) 1.00 
 
  
Yes 41350(77.9) 7846(83.8) 1.17(1.10 - 1.25) <0.001   
First LCNS assessment*       
 
  
After diagnosis 30680(74.2) 5825(74.2) 1.00 
 
  
Before/at diagnosis 9187(22.2) 1749(22.3) 1.08(1.01-1.15) 0.038   
Missing 1483(3.6) 272(3.5) 0.95(0.83-1.10) 
 
  
Place of LCNS assessment*       
 
  
In clinic 31095(75.2) 5993(76.4) 1.00 
 
  
Home visit 276(0.7) 49(0.6) 0.98(0.71 - 1.36) 
 
  
Ward visit 2776(6.7) 466(5.9) 0.95(0.85 - 1.06) 
 
  
Telephone 3784(9.2) 739(9.4) 1.10(1.00 - 1.20) 
 
  
Other 1043(2.5) 167(2.1) 1.00(0.84 - 1.20) 0.227   
Missing 2376(5.8) 432(5.5) 0.96(0.86 - 1.08) 
 
  
LCNS present at diagnosis*       
 
  
No  8935(21.6) 1510(19.3) 1.00 
 
  
Yes 31119(75.3) 6117(78.0) 1.13(1.06 - 1.20) <0.001   
Missing 1296(3.1) 219(2.8) 1.06(0.90 - 1.24) 
 
  
Anti-cancer treatment modality 
(all patients)       
 
  
No treatment 12297(18.9) 328(3.4) 1.00 
 
  
Surgery 19148(29.4) 2616(27.1) 4.65(4.09 - 5.29) 
 
  
Chemo and radio 14677(22.5) 3685(38.2) 8.01(7.04 - 9.11) 
 
  
Chemotherapy alone 8268(12.7) 2138(22.2) 8.64(7.58 - 9.85) 
 
  
Radiotherapy only 10790(16.6) 885(9.2) 2.67(2.34 - 3.05) <0.001   
NSCLC patients only:       
 
  
No treatment 11779(20.5) 301(3.7) 1.00 
 
  
Surgery 17326(30.1) 2396(29.7) 4.87(4.25 - 5.58) 
 
  
Chemo and radio 10274(17.9) 2521(31.3) 8.08(7.05 - 9.25) 
 
  
Chemotherapy alone 7606(13.2) 2001(24.8) 9.17(7.99 - 10.53) 
 
  
Radiotherapy only 10501(18.3) 847(10.5) 2.73(2.38 - 3.14) <0.001   
SCLC patients only:       
 
  
No treatment 187(3.4) 7(0.5) 1.00 
 
  
Surgery 89(1.6) 8(0.6) 2.27(0.77 - 6.69) 
 
  
Chemo and radio 4376(79.3) 1157(86.9) 7.96(3.67 - 17.27) 
 
  
Chemotherapy alone 616(11.2) 125(9.4) 5.33(2.41 - 11.79) 
 
  
Radiotherapy only 253(4.6) 34(2.6) 3.58(1.54 - 8.37) 0.432   
 
Abbreviations: CI: confidence interval; CPES: Cancer Patient Experience Survey; LCNS: lung cancer nurse specialist; MDT: multidisciplinary discussion; 
NLCA: National Lung Cancer Audit; NSCLC: non-small cell lung cancer; OR: odd ratio; SCLC: small cell lung cancer; TWW: Two-week wait 
Notes: Logistic regression model with ORs adjusted for all for gender, age, performance status, stage of cancer at diagnosis, ethnicity, socioeconomic 
deprivation, Charlson Index of comorbidity, route to diagnosis, lung cancer type and year of diagnosis. Missing not included in p-values. 





Supplementary Table 3: Multi-level logistic regression model of baseline, clinical, treatment and service characteristics 
comparing lung cancer patients included and not included in CPES 
 
Characteristic 
Total number of 
people(N=167,210) 
n  (%) 
Number of people 
in CPES (N=12,613)  
n (%) 
Adjusted OR of being in 
CPES (95% CI) p-value 
Year of diagnosis     
 
  
2009 25671(15.4) 1385(11.0) 1.00   
2010 26481(15.8) 1621(12.9) 1.18(1.09 - 1.28)   
2011 27712(16.6) 3020(23.9) 2.19(2.03 - 2.36)   
2012 29329(17.5) 3149(25.0) 1.91(1.77 - 2.07)   
2013 29422(17.6) 2856(22.6) 1.72(1.59 - 1.86)   
2014 28058(16.8) 534(4.2) 0.34(0.31 - 0.38)   
2015 537(0.3) 48(0.4) 1.48(1.08 - 2.03) <0.001 
Gender         
Male 91882(55.0) 6796(53.9) 1.00   
Female 75328(45.1) 5817(46.1) 1.06(1.02 - 1.10) 0.003 
Age (years)         
<65 41541(24.8) 4445(35.2) 1.00   
65-80 90087(53.9) 7326(58.1) 1.01(0.97 - 1.06)   
>80 35582(21.3) 842(6.7) 0.76(0.70 - 0.83) 0.103 
Stage         
SgIA 11002(6.6) 970(7.7) 1.00   
SgIB 10101(6.0) 1122(8.9) 1.28(1.16 - 1.41)   
SgIIA 5642(3.4) 837(6.6) 1.68(1.52 - 1.87)   
SgIIB 5370(3.2) 682(5.4) 1.57(1.41 - 1.76)   
SgIIIA 19104(11.4) 2241(17.8) 1.50(1.37 - 1.64)   
SgIIIB 14551(8.7) 1399(11.1) 1.15(1.04 - 1.28)   
SgIV 71519(42.8) 3856(30.6) 0.91(0.83 - 1.00) <0.001 
Missing 29921(17.9) 1506(11.9) 1.04(0.94 - 1.16)   
Performance status         
0 25464(15.2) 4354(34.5) 1.00   
1 46805(28.0) 5328(42.2) 0.86(0.82 - 0.90)   
2 27056(16.2) 1304(10.3) 0.60(0.56 - 0.65)   
3 30491(18.2) 415(3.3) 0.38(0.34 - 0.42)   
4 8115(4.9) 18(0.1) 0.12(0.08 - 0.19) <0.001 
Missing 29279(17.5) 1194(9.5) 0.68(0.63 - 0.73)   
Ethnicity         
White 139419(83.4) 11404(90.4) 1.00   
Black 1169(0.7) 88(0.7) 0.90(0.72 - 1.14)   
Asian 1977(1.2) 142(1.1) 0.86(0.72 - 1.04)   
Mixed 268(0.2) 23(0.2) 0.96(0.61 - 1.52)   
Other 939(0.6) 83(0.7) 1.02(0.80 - 1.30) 0.385 
Missing 23438(14.0) 873(6.9) 0.60(0.56 - 0.65)   
Socioeconomic deprivation quintile         
1-least deprived 22872(13.7) 1989(15.8) 1.00   
2 29596(17.7) 2525(20.0) 0.97(0.91 - 1.04)   
3 32934(19.7) 2590(20.5) 0.94(0.88 - 1.00)   
4 37148(22.2) 2650(21.0) 0.86(0.81 - 0.92)   
5-most deprived 44660(26.7) 2859(22.7) 0.79(0.74 - 0.84) <0.001 
Comorbidity (Charlson index)         
0 49643(29.7) 5208(41.3) 1.00   
1 32024(19.2) 2845(22.6) 0.98(0.93 - 1.04)   
2-3 28670(17.2) 1874(14.9) 0.88(0.83 - 0.93)   
4+ 56873(34.0) 2686(21.3) 0.83(0.79 - 0.88) <0.001 
Route to diagnosis         
GP referral 36496(21.8) 3112(24.7) 1.00   
Emergency presentation 53796(32.2) 1584(12.6) 0.73(0.68 - 0.78)   
Inpatient elective 2754(1.7) 214(1.7) 0.97(0.83 - 1.13)   
Other outpatient 18474(11.1) 1665(13.2) 0.96(0.90 - 1.03)   
TWW 53632(32.1) 5954(47.2) 1.08(1.03 - 1.14) <0.001 
Missing 2058(1.2) 84(0.7) 0.72(0.57 - 0.91)   
Lung cancer type         
NSCLC 145408(87.0) 10467(83.0) 1.00   
Carcinoid 1298(0.8) 159(1.3) 0.84(0.70 - 1.00)   





Supplementary table 3 continued: 
Characteristic Total number of 
people (%) 
Number of people 
in CPES (%) 
Adjusted OR of being in CPES 
(95% CI) p-value 
Anti-cancer treatment modality         
No treatment 60841(36.4) 391(3.1) 1.00   
Surgery 24544(14.7) 4036(32.0) 12.54(11.13 - 14.13)   
Chemo and radio 29066(17.4) 4610(36.6) 14.50(12.94 - 16.25)   
Chemotherapy alone 20962(12.5) 2466(19.6) 11.56(10.31 - 12.98)   
Radiotherapy only 31797(19.0) 1110(8.8) 3.69(3.27 - 4.15) <0.001 
 
Trust annual service size         
<150 new LC patients seen 47144(28.2) 3612(28.6) 1.00   
150-224 50742(30.4) 3741(29.7) 0.94(0.85 - 1.05)   
≥225 68473(41.0) 5240(41.5) 0.98(0.88 - 1.10) 0.641 
unknown/missing 851(0.5) 20(0.2) 0.51(0.27 - 0.98)   
Trust treatment specialty         
No specialty 31229(18.7) 1989(15.8) 1.00   
Surgical trust  42600(25.5) 3583(28.4) 1.24(1.08 - 1.43)   
Chemotherapy trust  93381(55.9) 7041(55.8) 1.14(1.02 - 1.28) 0.002 
 
Abbreviations: CI: confidence interval; CPES: Cancer Patient Experience Survey; GP: general practice; NLCA: National Lung 
Cancer Audit; NSCLC: non-small cell  
lung cancer; OR: odds ratio; SCLC: small cell lung cancer; TWW: Two-week wait 
      
Notes: Logistic regression model with ORs adjusted for all other variables in the table. Missing not included in p-values. 
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